BioSpace News Archive

Pressure BioSciences, Inc. today confirmed specific product rollout plans agreed in their wide-ranging partnership with science-driven skincare industry leader Dr. Denese SkinScience.

Nykode Therapeutics ASA (OSE: NYKD) today announced the presentation of positive preliminary safety and immunogenicity results from its Phase 1/2a study of VB10.NEO, a proprietary individualized therapeutic DNA cancer vaccine, in patients with locally advanced or metastatic solid tumors.

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patents over the last year on multiple ways to improve CAR-T therapies currently being utilized in the treatment of cancers.

Carisma Therapeutics Inc. today announced that the company will present at two healthcare industry conferences and one investor conference in the fourth quarter of 2022.

Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, reported today new non-clinical data on its lead candidate, immunogenic cell death inducer PT-112, and its effects on human prostate cancer cell mitochondria.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new Ocrevus® (ocrelizumab) data on disease progression and healthcare costs in patients with early-stage relapsing-remitting multiple sclerosis (RRMS) and long-term safety from all clinical trials in patients with relapsing MS (RMS) and primary progressive MS (PPMS).

SamanTree Medical, a medical technology company driven to support clinicians with their intraoperative decisions and improve cancer surgery outcomes, announced today the publication of clinical data unraveling the potential of its proprietary medical imaging platform, the Histolog® Scanner.

Gladstone Institutes and the Chan Zuckerberg Biohub signed an affiliation agreement to increase their research collaboration.

LEO Pharma Inc. announced that the British Journal of Dermatology published detailed results from a pooled safety analysis of Adbry™ from three pivotal Phase 3 trials, Phase 2 and Phase 2b trials of adult patients with moderate-to-severe atopic dermatitis.

Galera Therapeutics, Inc. (Nasdaq: GRTX) today announced the presentation of one-year tumor and renal function outcomes data from its Phase 3 ROMAN trial of avasopasem manganese 90 mg for radiotherapy-induced severe oral mucositis (SOM), as well as topline results from a recently completed meta-analysis of the ROMAN and GT-201 SOM trial results, at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.